logo-loader
Invitrocue Ltd

Invitrocue to discuss its unique Onco-PDO cancer test at Proactive CEO Sessions

The company’s Onco-PDO cancer screening service supports personalised clinical decisions for patients.

cancer
New agreement signed focusing on breast cancer models

Invitrocue Ltd’s (ASX:IVQ) Onco-PDO test takes a personalised approach and allows physicians to prescribe the most appropriate treatment regime for a particular type of cancer.

The Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a broad panel of chemotherapy drugs to support personalised clinical decisions.

Invitrocue co-founder and executive director Dr. Steven Fang will present to investors at the Sydney investor event on Monday, May 13 and at the Melbourne event on Tuesday, May 14.

Dr. Steven Fang

READ: Invitrocue signs agreement to develop new breast cancer models for its Onco-PDO test

The company recently signed a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB) for the development of new breast cancer models for its Onco-PDO test.

Under the agreement, professor Arial Zeng, an expert in stem cells during mammary development and breast cancer, will help Invitrocue to develop and optimise the protocols for the in vitro culture, propagation and expansion of patient-derived organoids (PDOs) from breast cancer patients with multiple breast cancer subtypes, including ER+, PR+, HER2+ and TNBC.

The intellectual property (IP) will be jointly owned by both parties and Invitrocue will be granted global commercialisation rights to any IP developed under the agreement.

Register for the CEO Sessions today

Sydney details, Monday, May 13, 2019

Melbourne details, Tuesday, May 14, 2019

Also featuring at both sessions will be Xanadu Mines Ltd (ASX:XAM), Zelda Therapeutics Ltd (ASX:ZLD), Oventus Medical Ltd (ASX:OVN and Infinity Lithium Corporation Ltd (ASX:INF).

Quick facts: Invitrocue Ltd

Price: $0.06

Market: ASX
Market Cap: $31.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Invitrocue Ltd named herein, including the promotion by the Company of Invitrocue Ltd in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Invitrocue leads market with disruptive technology and personalised oncology...

Invitrocue Ltd (ASX:IVQ) chief executive officer Steven Fang speaks to Proactive Investors about the oncology-focused company's development of cancer treatments by testing specific drugs on laboratory-controlled micro-tumours.    "We've been able to take some of these really...

on 20/5/19

2 min read